Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Resident, Internal Medicine, Duke University School of Medicine 2007 - 2010
  • M.D., Duke University School of Medicine 2007
• 

  Duke Appointment History

  • Medical Instructor in the Department of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Medicine 2013 - 2017
• Research
• 

  Selected Grants

  • ME 522 001 awarded by MEI Pharma, Inc. 2018 - 2023
  • TP-0903-102 awarded by Tolero Pharmaceuticals, Inc 2019 - 2023
  • BGB-3111-304 awarded by BeiGene, Ltd 2018 - 2023
  • D15-11094 awarded by Zhejiang DTRM Biopharma Co.Ltd. 2018 - 2023
  • UTX-TGR-501 awarded by TG Therapeutics, Inc 2018 - 2023
  • DFCI Obinutuzumab and Ibrutinib Protocol # 15-283 awarded by Dana Farber Cancer Institute 2017 - 2022
  • Ph 2 Study of TGR-1202 in Patients with CLL awarded by TG Therapeutics, Inc 2016 - 2021
  • Multi-Center, Open-Label Study of Ublituximab (TG-1101) in combination with TGR-1202 awarded by TG Therapeutics, Inc 2016 - 2021
  • Ph 3 of Ublituximab in Combination with TGR-1202 awarded by TG Therapeutics, Inc 2016 - 2021
  • Phase III study of ACP-196 vs Ibrutinib in High Risk CLL awarded by Acerta Pharma 2016 - 2021
  • A Phase II Study of Ibrutinib in combo with Fludarabine, Cyclophosphamide and Rituximab for young patients with CLL awarded by Dana Farber Cancer Institute 2015 - 2020
  • Phase 3 Study of Ublituximab in combination with Ibrutinib compared to Ibrutinib Alone in CLL pts. awarded by TG Therapeutics, Inc 2015 - 2020
  • Gilead GS-US 312 0133 awarded by Gilead Sciences, Inc. 2014 - 2019
  • Screening protocol to determine high risk cytogenetic features in previously treated CLL awarded by TG Therapeutics, Inc 2016 - 2017
  • A Phase II Study of PNT2258 in Patients with Richter's Transformation (RT). awarded by ProNAi Therapeutics, Inc. 2016 - 2017
  • MedImmune CD-ON-CAT-8015-1053 awarded by MedImmune, Inc. 2015 - 2017
  • GS-US-312-0123 awarded by Gilead Sciences, Inc. 2014 - 2017
  • A Phase I Trial of a Bcl-2 inhibitor and a MEK inhibitor for patients with relapsed indolent B-NHL awarded by Lymphoma Research Foundation of America 2014 - 2016
  • Phase 2 GS-US-339-0103 awarded by Gilead Sciences, Inc. 2013 - 2015
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Weinberg, J Brice, Danielle M. Brander, Dale J. Christensen, and Daphne R. Friedman. “Post-translational regulation could be determine functional differences between SET alpha and beta isoform - Response to Cristóbal et al..” Br J Haematol, May 1, 2019. https://doi.org/10.1111/bjh.15934.
       Full Text  Link to Item
    • Brander, Danielle M., Daphne R. Friedman, Alicia D. Volkheimer, Dale J. Christensen, Laura Z. Rassenti, Thomas J. Kipps, Eross Guadalupe, et al. “SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia..” British Journal of Haematology 184, no. 4 (February 2019): 605–15. https://doi.org/10.1111/bjh.15677.
       Full Text
    • Wierda, William G., John C. Byrd, Jeremy S. Abramson, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Jennifer Brown, et al. “NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019..” Journal of the National Comprehensive Cancer Network : Jnccn 17, no. 1 (January 2019): 12–20. https://doi.org/10.6004/jnccn.2019.0002.
       Full Text
    • Woyach, Jennifer A., Amy S. Ruppert, Nyla A. Heerema, Weiqiang Zhao, Allison M. Booth, Wei Ding, Nancy L. Bartlett, et al. “Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL..” The New England Journal of Medicine 379, no. 26 (December 2018): 2517–28. https://doi.org/10.1056/nejmoa1812836.
       Full Text
    • Mato, Anthony R., Lindsey E. Roeker, John N. Allan, John M. Pagel, Danielle M. Brander, Brian T. Hill, Bruce D. Cheson, et al. “Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial..” American Journal of Hematology 93, no. 11 (November 2018): 1394–1401. https://doi.org/10.1002/ajh.25261.
       Full Text
    • Mato, Anthony R., Meghan Thompson, John N. Allan, Danielle M. Brander, John M. Pagel, Chaitra S. Ujjani, Brian T. Hill, et al. “Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States..” Haematologica 103, no. 9 (September 2018): 1511–17. https://doi.org/10.3324/haematol.2018.193615.
       Full Text
    • Mato, Anthony R., Jennifer C. Samp, Geneviève Gauthier, Emi Terasawa, and Danielle M. Brander. “Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies..” Cancer Biology & Therapy 19, no. 7 (July 2018): 636–43. https://doi.org/10.1080/15384047.2018.1449616.
       Full Text
    • Mato, Anthony R., Chadhi Nabhan, Meghan C. Thompson, Nicole Lamanna, Danielle M. Brander, Brian Hill, Christina Howlett, et al. “Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis..” Haematologica 103, no. 5 (May 2018): 874–79. https://doi.org/10.3324/haematol.2017.182907.
       Full Text  Link to Item
    • Burris, Howard A., Ian W. Flinn, Manish R. Patel, Timothy S. Fenske, Changchun Deng, Danielle M. Brander, Martin Gutierrez, et al. “Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study..” The Lancet. Oncology 19, no. 4 (April 2018): 486–96. https://doi.org/10.1016/s1470-2045(18)30082-2.
       Full Text
    • Thompson, M., D. Brander, C. Nabhan, and A. Mato. “Minimal residual disease in chronic lymphocytic leukemia in the era of novel agents a review.” Jama Oncology 4, no. 3 (March 1, 2018): 394–400. https://doi.org/10.1001/jamaoncol.2017.2009.
       Full Text
    • Wierda, William G., John C. Byrd, Jeremy S. Abramson, Seema Bhat, Greg Bociek, Danielle Brander, Jennifer Brown, et al. “Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology..” Journal of the National Comprehensive Cancer Network : Jnccn 15, no. 11 (November 2017): 1414–27. https://doi.org/10.6004/jnccn.2017.0165.
       Full Text
    • Mato, A. R., B. T. Hill, N. Lamanna, P. M. Barr, C. S. Ujjani, D. M. Brander, C. Howlett, et al. “Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients..” Annals of Oncology : Official Journal of the European Society for Medical Oncology 28, no. 5 (May 2017): 1050–56. https://doi.org/10.1093/annonc/mdx031.
       Full Text
    • Brander, Danielle M. “Rationale for combinatory chronic lymphocytic leukaemia treatment paradigms in the era of the B-cell receptor pathway and anti-apoptotic inhibitors: how do we mix, match, and move forward?.” British Journal of Haematology 176, no. 3 (February 2017): 337–40. https://doi.org/10.1111/bjh.14446.
       Full Text
    • Seymour, John F., Shuo Ma, Danielle M. Brander, Michael Y. Choi, Jacqueline Barrientos, Matthew S. Davids, Mary Ann Anderson, et al. “Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study..” The Lancet. Oncology 18, no. 2 (February 2017): 230–40. https://doi.org/10.1016/S1470-2045(17)30012-8.
       Full Text
    • Strati, Paolo, Mark Lanasa, Timothy G. Call, Jose F. Leis, Danielle M. Brander, Betsy R. LaPlant, Adam M. Pettinger, et al. “Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial..” The Lancet. Haematology 3, no. 9 (September 2016): e407–14. https://doi.org/10.1016/s2352-3026(16)30064-3.
       Full Text
    • Friedman, Daphne R., Mark C. Lanasa, Patricia H. Davis, Sallie D. Allgood, Karen M. Matta, Danielle M. Brander, Youwei Chen, et al. “Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies..” Leukemia & Lymphoma 55, no. 5 (May 2014): 1067–75. https://doi.org/10.3109/10428194.2013.824080.
       Full Text
    • Brander, Danielle, David Rizzieri, Jon Gockerman, Louis Diehl, Thomas Charles Shea, Carlos Decastro, Joseph O. Moore, and Anne Beaven. “Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma..” Leukemia & Lymphoma 54, no. 12 (December 2013): 2627–30. https://doi.org/10.3109/10428194.2013.784969.
       Full Text
    • Brander, Danielle M., and Anne W. Beaven. “Update on treatment of follicular non-Hodgkin's lymphoma: focus on potential of bortezomib..” Patient Preference and Adherence 6 (January 2012): 239–51. https://doi.org/10.2147/PPA.S23241.
       Full Text
    • Bean, Gregory R., Andrew D. Bryson, Patrick G. Pilie, Vanessa Goldenberg, Joseph C. Baker, Catherine Ibarra, Danielle M. U. Brander, et al. “Morphologically normal-appearing mammary epithelial cells obtained from high-risk women exhibit methylation silencing of INK4a/ARF..” Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 13, no. 22 Pt 1 (November 2007): 6834–41. https://doi.org/10.1158/1078-0432.ccr-07-0407.
       Full Text

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.